SCHEMBL4516252

SCHEMBL4516252

O=C1C(Cc2ccc(OCCOc3ccccc3)cc2Cl)CCN1C1CCCCC1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 2/20 0.55
CTSK P43235 1/20 0.38
FFAR1 O14842 3/20 0.38
HPGD P15428 1/20 0.38
GLA P06280 1/20 0.38
MAOA P21397 1/20 0.37
MAOB P27338 1/20 0.37
KDM4E B2RXH2 1/20 0.36
POLB P06746 1/20 0.36
HCRTR1 O43613 1/20 0.36
HCRTR2 O43614 1/20 0.36
TP53 P04637 1/20 0.36
CCR5 P51681 1/20 0.36
DRD2 P14416 1/20 0.35
DRD4 P21917 1/20 0.35
DRD3 P35462 1/20 0.35
HRH3 Q9Y5N1 1/20 0.35
S1PR1 P21453 1/20 0.35
PRKX P51817 1/20 0.35
ACVR1 Q04771 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4499324 0.91 HSD11B1 (0.54) HSD11B1MAOAMAOBHRH3S1PR1
SCHEMBL4514386 0.90 HSD11B1 (0.46) HSD11B1HPGDKDM4EHCRTR1HCRTR2
SCHEMBL3002570 0.90 HSD11B1 (0.57) HSD11B1FFAR1CCR5HRH3OPRM1
SCHEMBL4519338 0.89 HSD11B1 (0.60) HSD11B1MAOAMAOBHRH3S1PR1
SCHEMBL4525800 0.89 HSD11B1 (0.47) HSD11B1FFAR1HPGDKDM4EPOLB
SCHEMBL13674511 0.89 HSD11B1 (0.47) HSD11B1FFAR1HPGDMAOAMAOB
SCHEMBL4513272 0.89 HSD11B1 (0.54) HSD11B1FFAR1MAOAMAOBHRH3
SCHEMBL4521181 0.88 HSD11B1 (0.46) HSD11B1FFAR1HPGDKDM4EPOLB
Hydrochloric Acid SCHEMBL4514348 0.88 HSD11B1 (0.46) HSD11B1FFAR1HPGDMAOAMAOB
SCHEMBL4520465 0.88 HPGD (0.48) HSD11B1FFAR1HPGDKDM4EPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090264650-A1 Prophylactic/Therapeutic Agent for Diabetes TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-22 US disclosed
US-20090264650-A1 Prophylactic/Therapeutic Agent for Diabetes TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-22 US disclosed
US-20090264650-A1 Prophylactic/Therapeutic Agent for Diabetes TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-22 US disclosed
EP-1864971-A1 PROPHYLACTIC/THERAPEUTIC AGENT FOR DIABETES Takeda Pharmaceutical Company Limited (JP) 2007-12-12 EP disclosed
EP-1864971-A1 PROPHYLACTIC/THERAPEUTIC AGENT FOR DIABETES Takeda Pharmaceutical Company Limited (JP) 2007-12-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264650-A1 Prophylactic/Therapeutic Agent for Diabetes HSD11B1, HSD17B1, HSD11B2 HSD11B1 1/4885CTSK 3731/4885FFAR1 326/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.